InvestorsHub Logo
Followers 51
Posts 9097
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Friday, 04/07/2023 1:05:41 AM

Friday, April 07, 2023 1:05:41 AM

Post# of 13469
MRNA-4157/V940, AN INVESTIGATIONAL PERSONALIZED MRNA CANCER VACCINE, IN COMBINATION WITH KEYTRUDA(R) (PEMBROLIZUMAB), RECEIVES PRIME SCHEME DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR ADJUVANT TREATMENT OF PATIENTS WITH HIGH-RISK STAGE III/IV MELANOMA FOLLOWING COMPLETE RESECTION

https://investors.modernatx.com/news/news-details/2023/MRNA-4157V940-an-Investigational-Personalized-MRNA-Cancer-Vaccine-in-Combination-With-KeytrudaR-Pembrolizumab-Receives-Prime-Scheme-Designation-From-the-European-Medicines-Agency-for-Adjuvant-Treatment-of-Patients-With-High-Risk-Stage-IIIIV-Melanoma-/default.aspx
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News